Search
Menu
Home
HTB
2016
June
HTB
June 2016
Contents
Editorial
May/June 2016: Volume 17 Number 5/6
In memory
In Memory: Paul Blanchard, cofounder HIV i-Base
Treatment alerts
NHS England confuses arse and elbow: block to PrEP ignores UK HIV crisis and will send PEP services into chaos
Conference reports
22nd Annual BHIVA Conference, 19-22 April 2016, Manchester
New HBV drugs and non-viral liver disease in HIV positive people
Non-AIDS mortality in England and Wales in HIV positive vs general population
High prevalence of multiple high-risk HPV infections in young HIV positive gay men
Anal cancer and HPV screening in HIV positive people
Increasing demand for community treatment information services
Non alcohol fatty acid liver disease: an emerging problem
HIV positive people on ART have impaired alveolar immunity
International Liver Congress (EASL) 2016, 13-18 April 2016, Barcelona
High cure rates using generic hepatitis C drugs bought online: EASL supports lower cost access for Western countries
Studies of new generic $300 HepC combination of ravidasvir and sofosbuvir for low-income countries
23rd Conference on Retroviruses and Opportunistic Infections (CROI 2016), 22-25 February 2016, Boston
No effect of tenofovir on infant bone mineral content in African study
Use of modelling to predicting paediatric dosing of long acting antiretrovirals
Nevirapine dosing for treatment of neonates
START substudies: increased quality of life from earlier treatment but no impact on vascular function or cardiovascular markers
Six-week ledipasvir/sofosbuvir in HIV positive patients with acute HCV
6th International Workshop on HIV & Women, 20-21 February 2016, Boston
Doravirine can be co-administered with oral contraceptives
No increased risk of birth defects with darunavir: findings from the Antiretroviral Pregnancy Registry
Antiretrovirals
FTC/TAF dual-nuke approved in the US and Europe
Paediatric labeling expanded, and additional tablet strengths for FTC/TDF
Treatment access
Timeline for access to generic dolutegravir: what still needs to be done
Botswana “Treat All” programme will move to universal treatment with dolutegravir as first-line ART
South Africa takes bold step to provide HIV treatment for all
Side effects
Persistent HPV infection may be related to tissue type in HIV positive people
On the web
Community reports
PDFs
May/June 2016: Volume 17 Number 5/6
HTB RSS
Early access
Early phase 1 HIV vaccine study launched in the US and South Africa
21 September 2023
High rates of re-suppression with dolutegravir in the ADVANCE study
19 September 2023
EU approves cabotegravir as injectable PrEP
19 September 2023
Altered kidney function associated with alcohol and cannabis use by women living with HIV
13 September 2023
All early access reports
Current issues
September 2023
August 2023
June 2023
Back issues
Special report
Latest statistics on HIV in the UK: data for 2021
1 December 2022
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage